EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$8.32
-0.07 (-0.83%)
▼
5d:
+3.1%
30d:
-0.12%
90d:
+3.1%
BUY
HIGH Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EBS trading at deep discount. Market pricing in -14.5% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: EBS trading at deep discount. Market pricing in -14.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.19
Based on -0.1% avg growth
INTRINSIC VALUE TODAY
$8.19
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $8.32, which is considered fair relative to its 30-day fair value range of $8.05 to $8.97. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.1) compared to its historical average (14.6). Remarkably, the market is currently pricing in an annual earnings decline of 14.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $7.56, while resistance sits at $9.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+44.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $7.56, while resistance sits at $9.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+44.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.05 -
$8.97
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.2% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$8.05 -
$8.97
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.62
(7.5%)
Support & Resistance Levels
Support Level
$7.56
Resistance Level
$9.00
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.14
Wall Street Target
$12.00
(+44.2%)
Revenue Growth (YoY)
-29.7%
Earnings Growth (YoY)
-93.8%
Profit Margin
-1.3%
Valuation Discount vs History
-14.5% cheaper
PE vs Historical
9.1 vs 14.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.5%
(market-implied from PE analysis)
1-Year Target
$7.49
(-10%)
2-Year Target
$6.74
(-19%)
3-Year Target
$6.07
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→15)
$9.69
(+16%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: -4.2%)
$17.53
(+111%)
Base:
(SPY PE: 9.1, Growth: -4.2%)
$7.31
(-12%)
Bear:
(PE: 7.8, Growth: -4.2%)
$6.22
(-25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.1 to 14.6
Stabilization Target:
$13.29
(+59.7%)
PE Expansion Potential:
+59.7%
Share & Embed Analysis
Last updated: June 13, 2026 8:58 AM ET
Data refreshes hourly during market hours. Next update: 9:58 AM
Data refreshes hourly during market hours. Next update: 9:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 64 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 65 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 57 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$66 | 67 BUY |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
